Influenza vaccination coverage rate in children: reasons for a failure and how to go forward.

Abstract:

:Based on an increasingly extensive literature expressing the large interest in the field, this paper gives an overview of different aspects of influenza prevention in children. It relies on paradoxes. First, the heaviest part of the burden is well demonstrated in the youngest infants by numerous epidemiological data elsewhere. On the contrary, with older children, the prevention by influenza vaccines is more efficacious-without notable side effects. Second, the available TIV vaccines are 60 years old and the requests of registration and regulation of vaccines have evolved. There is a specific need in children: it is time to re-discuss the pragmatic utilization of influenza vaccines (full dose in the youngest patient? More flexibility regarding the interval between the two required doses in vaccine-naïve children), and to change from a compassionate use to a targeted research and adapted vaccines considering the limits of TIV in the youngest children. Third, influenza virus transmission is the highest in children in semi-close communities (day-care centers, schools), diffusing to households and more largely to the population. A restricted policy on high risk groups (roughly 10% in a pediatric population, all medical conditions including asthma, for whom influenza vaccine coverage is a 15-75% range) is far below the estimated threshold of 45% coverage rate to limit the virus circulation by an indirect impact during seasonal epidemics. Fourth, public health decisions in the vaccination field are usually taken from top to bottom. The pandemic A/H1N1 has toughly demonstrated that "forgetting" about the perception and expectations of the public and the parents nearly created conflicts and at least a strong resistance impeding the quality of a program worked on for a long time ahead. Fifth, and not the least, HCPs are pivotal in influenza vaccination mostly trusted by the parents. Too often, they are not backed by a national and clear support and they need to reinforce their knowledge on the disease and the vaccines.

journal_name

Hum Vaccin Immunother

authors

Olivier CW

doi

10.4161/hv.8.1.18278

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

107-18

issue

1

eissn

2164-5515

issn

2164-554X

pii

18278

journal_volume

8

pub_type

杂志文章,评审
  • Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.

    abstract::The objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6-month or a 3-8 -y interval between two HPV vaccine doses. The results from two clinical trials, conducted by the same team in the same region, with serological assays performed at the same laboratory using the same ELISA m...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1080/21645515.2019.1605278

    authors: Gilca V,Sauvageau C,Panicker G,De Serres G,Schiller J,Ouakki M,Unger ER

    更新日期:2019-01-01 00:00:00

  • Willingness to pay for an Ebola vaccine during the 2014-2016 ebola outbreak in West Africa: Results from a U.S. National sample.

    abstract::The 2014-2016 Ebola virus outbreak in West Africa led to advances in the development of vaccines against Ebola. This study examined factors associated with willingness to pay for an Ebola vaccine among a U.S. national sample during the recent Ebola outbreak. From April 30-May 8, 2015, a national survey was conducted u...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1423928

    authors: Painter JE,von Fricken ME,Viana de O Mesquita S,DiClemente RJ

    更新日期:2018-07-03 00:00:00

  • Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial.

    abstract::Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-HPV type at first vaccination (baseline) remains unclear. This post-hoc...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1829411

    authors: Hu S,Xu X,Zhu F,Hong Y,Hu Y,Zhang X,Pan Q,Zhang W,Zhang C,Yang X,Yu J,Zhu J,Zhu Y,Chen F,Zhao S,Karkada N,Tang H,Bi D,Struyf F,Zhao F

    更新日期:2020-11-12 00:00:00

  • Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.

    abstract::Varicella zoster virus (VZV) is primarily known for causing varicella in childhood, but can reactivate again as herpes zoster (HZ) after a period of latency, mainly in persons older than 50 years. Universal varicella vaccination was introduced in Germany in 2004, while HZ vaccination has not been recommended yet. We a...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1135279

    authors: Horn J,Karch A,Damm O,Kretzschmar ME,Siedler A,Ultsch B,Weidemann F,Wichmann O,Hengel H,Greiner W,Mikolajczyk RT

    更新日期:2016-07-02 00:00:00

  • Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China.

    abstract:INTRODUCTION:Enterovirus A71(EV-A71)-associated hand, foot, and mouth disease (HFMD) has been reported worldwide, and poses a particularly heavy burden on patients, families, and society in China. Three Chinese companies have licensed inactivated EV-A71 vaccines, all of which have demonstrated good efficacy for prevent...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1581539

    authors: Wang X,An Z,Huo D,Jia L,Li J,Yang Y,Liang Z,Wang Q,Wang H

    更新日期:2019-01-01 00:00:00

  • Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran.

    abstract::Eight months after the mass immunization campaign of November 2015 against measles and rubella in the southeast of Iran, in order to evaluate the sero-immunity level of the people living in the mentioned region, a serosurvey study was performed. Using a multi-stage probability proportional to size cluster sampling, th...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1436920

    authors: Izadi S,Zahraei SM,Mokhtari-Azad T

    更新日期:2018-06-03 00:00:00

  • Vaccination among Polish university students. Knowledge, beliefs and anti-vaccination attitudes.

    abstract::Anti-vaccination movement has existed as long as the vaccines themselves, but its mode of action and social influences evolved over time. Such attitude with no doubt has negative impact on vaccination rates and eradication of infectious diseases. In this study, we used an online survey to examine vaccination attitudes...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1365994

    authors: Zarobkiewicz MK,Zimecka A,Zuzak T,Cieślak D,Roliński J,Grywalska E

    更新日期:2017-11-02 00:00:00

  • Small molecule drugs with immunomodulatory effects in cancer.

    abstract::Immunotherapy shows promise for positively changing the landscape of the management of many advanced solid tumors, including gastrointestinal (GI) malignancies. Many of these developments have been focused on vaccine-based, monoclonal antibody therapies and more recently, checkpoint inhibitors, although many small mol...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1057363

    authors: Murphy AG,Zheng L

    更新日期:2015-01-01 00:00:00

  • Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.

    abstract:UNLABELLED:NmenB vaccine (4CMenB) is now available, but studies on the cost-effectiveness of vaccine introduction in a country outbreak situation are lacking. The aim of this study was to evaluate the cost-effectiveness of 4CMenB in the context of a hypothetical epidemic outbreak in Chile. We analyzed the direct and in...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1010885

    authors: Izquierdo G,Torres JP,Santolaya ME,Valenzuela MT,Vega J,Chomali M

    更新日期:2015-01-01 00:00:00

  • Noninvasive vaccination against infectious diseases.

    abstract::The development of a successful vaccine, which should elicit a combination of humoral and cellular responses to control or prevent infections, is the first step in protecting against infectious diseases. A vaccine may protect against bacterial, fungal, parasitic, or viral infections in animal models, but to be effecti...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1461296

    authors: Zheng Z,Diaz-Arévalo D,Guan H,Zeng M

    更新日期:2018-07-03 00:00:00

  • Key considerations for successful implementation of maternal immunization programs in low and middle income countries.

    abstract::The Maternal Neonatal Tetanus Elimination program is proof of concept for the feasibility and potential for maternal immunization to reduce neonatal mortality particularly in low and middle-income countries. Introduction of any additional vaccine into the antenatal space, such as Influenza and Pertussis, and potential...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1564433

    authors: Krishnaswamy S,Lambach P,Giles ML

    更新日期:2019-01-01 00:00:00

  • Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.

    abstract::One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R II or MMR-RIT at 12...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/21645515.2017.1309486

    authors: Berry AA,Abu-Elyazeed R,Diaz-Perez C,Mufson MA,Harrison CJ,Leonardi M,Twiggs JD,Peltier C,Grogg S,Carbayo A,Shapiro S,Povey M,Baccarini C,Innis BL,Henry O

    更新日期:2017-07-03 00:00:00

  • A physician's guide to the 2-dose schedule of MenB-FHbp vaccine.

    abstract::Meningococcal serogroup B (MenB) is the predominant cause of invasive meningococcal disease in the United States, with older adolescents and young adults attending college at increased risk. Notably, MenB caused all meningococcal disease outbreaks at US colleges between 2011 and 2018. MenB disease is vaccine-preventab...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2019.1596711

    authors: McDaniel A,Dempsey A,Srivastava A

    更新日期:2019-01-01 00:00:00

  • Overcoming barriers to HPV vaccination: A randomized clinical trial of a culturally-tailored, media intervention among African American girls.

    abstract::Although genital HPV is the most prevalent STI in the US, rates of vaccination uptake among high-risk subgroups remain low. Investigations of vaccine compliance have mainly targeted mother-daughter dyads, which in some settings may prove difficult. This study examines an innovative culturally tailored, computer-delive...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/21645515.2015.1070996

    authors: DiClemente RJ,Murray CC,Graham T,Still J

    更新日期:2015-01-01 00:00:00

  • DNA is an efficient booster of dendritic cell-based vaccine.

    abstract::DC-based therapeutic vaccines as a promising strategy against chronic infections and cancer have been validated in several clinical trials. However, DC-based vaccines are complex and require many in vitro manipulations, which makes this a personalized and expensive therapeutic approach. In contrast, DNA-based vaccines...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1020265

    authors: Li J,Valentin A,Beach RK,Alicea C,Felber BK,Pavlakis GN

    更新日期:2015-01-01 00:00:00

  • Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study.

    abstract::Rotavirus (RV) infection is the primary cause for childhood gastroenteritis worldwide. In Korea, RV infection is most common among children less than 5 years of age. This post-licensure study was conducted to further evaluate the RV vaccine (RIX4414) to provide additional local clinical data to the Korean Food and Dru...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/hv.19853

    authors: Kim JS,Bae CW,Lee KY,Park MS,Choi YY,Kim KN,Kim JD,Park WS,Sin JB,Kim EA,Lee SG,Kim CS,Cha SH,Hong YJ,Shin SM,Shim GH,Choi KM,Yang JW,Liu A,Suryakiran PV,Han HH

    更新日期:2012-06-01 00:00:00

  • Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.

    abstract::The four-component meningococcal serogroup B vaccine (4CMenB) contains antigens present in the majority of meningococci causing invasive meningococcal disease (IMD) and may potentially offer protection against strains belonging to non-B serogroups. This study aimed to evaluate the ability of 4CMenB-induced antibodies ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1855951

    authors: Fazio C,Biolchi A,Neri A,Tomei S,Vacca P,Ambrosio L,Palmieri A,Mori E,La Gaetana R,Pizza M,Giuliani MM,Serino L,Stefanelli P

    更新日期:2021-01-31 00:00:00

  • Influenza vaccine effectiveness against medically attended influenza illness in Beijing, China, 2014/15 season.

    abstract::Influenza vaccination is the most effective way of preventing influenza infections but its coverage is extremely low in China. Poor influenza vaccine effectiveness (VE) was reported in the 2014/15 season in some Northern Hemisphere countries with a predominance of H3N2 viruses belonging to the 3C.2a clade. However, th...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1359364

    authors: Ma C,Pan Y,Zhang L,Zhang Y,Wu S,Sun Y,Duan W,Zhang M,Wang Q,Yang P

    更新日期:2017-10-03 00:00:00

  • Maternal immunization. Clinical experiences, challenges, and opportunities in vaccine acceptance.

    abstract::Maternal immunization holds tremendous promise to improve maternal and neonatal health for a number of infectious conditions. The unique susceptibilities of pregnant women to infectious conditions, as well as the ability of maternally-derived antibody to offer vital neonatal protection (via placental transfer), togeth...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/21645515.2014.970901

    authors: Moniz MH,Beigi RH

    更新日期:2014-01-01 00:00:00

  • Q fever vaccination: Australian animal science and veterinary students' One Health perspectives on Q fever prevention.

    abstract::Unvaccinated animal science and veterinary students are at risk of Q fever, a vaccine-preventable zoonotic disease transmitted from animals to humans. We investigated students' perspectives on Q fever prevention using a One Health approach combining animal, human and environmental health. Animal science and veterinary...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1829900

    authors: Rahaman MR,Milazzo A,Marshall H,Chaber AL,Bi P

    更新日期:2020-11-12 00:00:00

  • Field seasonal influenza vaccine effectiveness: evaluation of the screening method using different sources of data during the 2010/2011 French influenza season.

    abstract::Thanks to the screening method, we estimated among target groups the 2010/2011 field vaccine effectiveness (FVE) against laboratory confirmed influenza cases seen in general practice. We also compared the values of FVE estimations obtained by using three sources of the population vaccination coverage (VC) based on thr...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.25513

    authors: Falchi A,Souty C,Grisoni ML,Mosnier A,Hanslik T,Daviaud I,Varesi L,Kerneis S,Carrat F,Blanchon T

    更新日期:2013-11-01 00:00:00

  • Tetanus toxoid vaccine: elimination of neonatal tetanus in selected states of India.

    abstract::Tetanus is caused by a neurotoxin produced by Clostridium tetani (C. tetani), a spore-forming bacterium. Infection begins when tetanus spores are introduced into damaged tissue. Tetanus is characterized by muscle rigidity and painful muscle spasms caused by tetanus toxin's blockade of inhibitory neurons that normally ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.21145

    authors: Verma R,Khanna P

    更新日期:2012-10-01 00:00:00

  • Modeling the hepatitis A epidemiological transition in Brazil and Mexico.

    abstract:BACKGROUND:Many low- to middle-income countries have completed or are in the process of transitioning from high or intermediate to low endemicity for hepatitis A virus (HAV). Because the risk of severe hepatitis A disease increases with age at infection, decreased incidence that leaves older children and adults suscept...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1323158

    authors: Van Effelterre T,Guignard A,Marano C,Rojas R,Jacobsen KH

    更新日期:2017-08-03 00:00:00

  • Achieving high HPV vaccine completion rates in a pediatric clinic population.

    abstract::Objective: To evaluate the efficacy of an intervention utilizing patient navigators (PNs) to 1) educate families on human papillomavirus (HPV) vaccination in a clinic setting and 2) provide personalized reminders for follow-up. Method: Families with 9-17 year-old children who had no record of completing the HPV vaccin...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1533778

    authors: Berenson AB,Rupp R,Dinehart EE,Cofie LE,Kuo YF,Hirth JM

    更新日期:2019-01-01 00:00:00

  • Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.

    abstract::In the clinical trials of the quadrivalent human papillomavirus (qHPV) vaccine, antibodies were measured by a competitive Luminex immunoassay (HPV-4 cLIA). A nine-valent HPV (9vHPV) vaccine targeting the types in the qHPV vaccine (HPV6/11/16/18), as well as 5 of the next most frequent HPV types found in cervical cance...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.29205

    authors: Roberts C,Green T,Hess E,Matys K,Brown MJ,Haupt RM,Luxembourg A,Vuocolo S,Saah A,Antonello J

    更新日期:2014-01-01 00:00:00

  • Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors.

    abstract::In a blinded randomized trial, preoperative receipt of the Merck V710 Staphylococcus aureus vaccine was associated with a higher mortality rate than placebo in patients who later developed postoperative S. aureus infections. Of the tested patients, all 12 V710 recipients (but only 1 of 13 placebo recipients) with unde...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.34407

    authors: McNeely TB,Shah NA,Fridman A,Joshi A,Hartzel JS,Keshari RS,Lupu F,DiNubile MJ

    更新日期:2014-01-01 00:00:00

  • Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine.

    abstract::Purpose: Gaps remain in the public's knowledge of the human papillomavirus (HPV). We assessed racial/ethnic and gender disparities in knowledge and awareness of HPV and the HPV vaccine among US adults. METHODS:Data from the Health Information National Trends Survey 4 Cycle 3 (September - December 2013) and Cycle 4 (A...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1363133

    authors: Adjei Boakye E,Tobo BB,Rojek RP,Mohammed KA,Geneus CJ,Osazuwa-Peters N

    更新日期:2017-11-02 00:00:00

  • Vaccinations-Between free will and coercion.

    abstract::Dynamically changing social situation associated with migrations, increasing freedom rights, popularity of anti-vaccine movements and the resulting from that decrease in herd immunity, forces the medical society and the governments of various countries to reflect on the attitude toward vaccinations. Issues of freedoms...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2016.1162936

    authors: Patryn RK,Zagaja A

    更新日期:2016-08-02 00:00:00

  • Prevention of pertussis: An unresolved problem.

    abstract::Pertussis is a highly contagious respiratory disease caused by Bordetella pertussis. However, after the introduction of the whole-cell pertussis vaccine (wP), the annual incidence rates of the disease progressively declined. Despite this result, the inclusion of wP in the national immunization schedule of infants and ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1480298

    authors: Esposito S,Principi N

    更新日期:2018-01-01 00:00:00

  • Acute hepatitis A in an elderly patient after care worker travel to high endemicity country.

    abstract::Hepatitis A virus (HAV) is considered one of the most important vaccine-preventable diseases in travelers. HAV spreads from person to person via the fecal-oral route and gives rise to an estimated 1.4 million cases worldwide each year. In developing countries with poor sanitary conditions people tend to be infected du...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.25719

    authors: Aasheim ET,Seymour M,Balogun K,Ngui SL,Williams CJ,Shankar AG

    更新日期:2013-11-01 00:00:00